PMS-SOLIFENACIN 5 MG
SOLIFENACIN SUCCINATE : 5 MG · DIN 02417723 · PHARMASCIENCE INC
Health Canada status: MARKETED
What is PMS-SOLIFENACIN?
PMS-SOLIFENACIN 5 MG contains SOLIFENACIN SUCCINATE : 5 MG. It is listed in the Health Canada Drug Product Database under DIN 02417723, held by PHARMASCIENCE INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 28-Oct-2015. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is PMS-SOLIFENACIN used for?
Treatment of overactive bladder in adults with symptoms of urge urinary incontinence, urinary urgency and urinary frequency.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02417723 |
|---|---|
| Brand name | PMS-SOLIFENACIN |
| Generic / active ingredient | SOLIFENACIN SUCCINATE : 5 MG |
| Manufacturer | PHARMASCIENCE INC |
| Strength | 5 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | G04BD08 SOLIFENACIN |
| AHFS class | 86:12.04 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 28-Oct-2015 |
| Original market date | 2015-10-28 00:00:00 |
How is it administered?
Recommended dose: 5 mg once daily; may increase to 10 mg if well-tolerated. Swallow whole with liquids, with or without food. Maximum effect determined after 4 weeks.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in the provided text (Table of Contents lists 'STORAGE AND STABILITY' on page 15, but the page content is missing).
How is it supplied?
Not explicitly detailed in the provided text (refers to 5 mg and 10 mg strengths).
Contraindications
Urinary retention, dialysis-dependent, gastroparesis, narrow angle glaucoma, and hypersensitivity to the drug or any ingredient.
Warnings and precautions
Risk of angioedema and anaphylaxis; caution in patients with bladder outflow obstruction, decreased GI motility, or QT prolongation. May cause blurred vision and somnolence.
What can be used instead?
Other Canadian products sharing ATC code G04BD08 SOLIFENACIN. 24 of 42 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ACH-SOLIFENACIN SUCCINATE | 10 MG | TABLET | ACCORD HEALTHCARE INC | MARKETED | DIN 02439352 |
| ACH-SOLIFENACIN SUCCINATE | 5 MG | TABLET | ACCORD HEALTHCARE INC | MARKETED | DIN 02439344 |
| AURO-SOLIFENACIN | 10 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02446383 |
| AURO-SOLIFENACIN | 5 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02446375 |
| BIO-SOLIFENACIN | 10 MG | TABLET | BIOMED PHARMA | MARKETED | DIN 02516527 |
| BIO-SOLIFENACIN | 5 MG | TABLET | BIOMED PHARMA | MARKETED | DIN 02516519 |
| JAMP SOLIFENACIN SUCCINATE | 10 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02428938 |
| JAMP SOLIFENACIN SUCCINATE | 5 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02428911 |
| PMS-SOLIFENACIN | 10 MG | TABLET | PHARMASCIENCE INC | MARKETED | DIN 02417731 |
| PRZ-SOLIFENACIN | 10 MG | TABLET | PHARMARIS CANADA INC | MARKETED | DIN 02493047 |
Who else supplies SOLIFENACIN worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. SOLIFENACIN appears in 235 registered pack listings across 11 markets, published on 9 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.